How drug companies continue to hide the true story of Tamiflu and other drugs from the American public

by | Apr 12, 2012 | antidepressants, antipsychotic drugs, clinical trials, drug marketing, FDA, health care costs, patient care, pharmaceutical industry, scientific misconduct

I’ve been reading Dr. David Healy’s new book, Pharmageddon, and while some of it may seem like old news, I was struck by his fresh analysis of how the pharmaceutical industry has turned the original purpose of clinical trials inside out. As Healy, a noted...

When it comes to scientific misconduct, should there be a statute of limitations?

by | Feb 7, 2012 | antidepressants, clinical trials, conflicts of interest, FDA, ghostwriting, pharmaceutical industry, scientific journal retractions, scientific misconduct

I was hesitant to weigh in at first when I learned that Brown University’s School of Medicine had decided not to pressure a psychiatric journal to retract the seriously flawed Paxil study that I wrote about in Side Effects. After all, Brown has been covering up...

International group seeks Brown University’s help in retracting controversial Paxil study

by | Nov 18, 2011 | antidepressants, conflicts of interest, drug marketing, ghostwriting, pharmaceutical industry, scientific journal retractions, scientific misconduct

The international research organization Healthy Skepticism has called on Brown University to help convince a psychiatric journal to retract the controversial Paxil trial that I wrote about in Side Effects, according to the Brown Daily Herald. The principal...

Allegations of fraud and extensive ghostwriting form core of upcoming Texas case against Johnson & Johnson

by | Nov 2, 2011 | antipsychotic drugs, conflicts of interest, drug marketing, ghostwriting, patient care, pharmaceutical industry, scientific misconduct, Uncategorized

On November 28, the Texas Attorney General is expected to begin a landmark trial against Johnson & Johnson on charges that the pharmaceutical giant “subverted scientific integrity” by paying off academic psychiatrists and state officials to boost the...

UPenn President is urged to resign as chair of Obama’s bioethics commission for ignoring scientific misconduct allegations

by | Jul 11, 2011 | antidepressants, conflicts of interest, ghostwriting, scientific misconduct, university industry collaboration

The Project on Government Oversight (POGO) has called on President Obama to remove Amy Gutmann, University of Pennsylvania’s president, as chair of his presidential commission for the study of bioethical issues. The reason: Gutmann did nothing to sanction the...